Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867984 | 0.85 | HSD17B10 (0.46) | HSD17B10KMT2ARXFP1MEN1KDM4E | |
| SCHEMBL1337392 | 0.85 | HSD17B10 (0.46) | HSD17B10KMT2ARXFP1MEN1KDM4E | |
| SCHEMBL3569292 | 0.82 | KDM4E (0.58) | HSD17B10KMT2ARXFP1EGFRKDM4E | |
| SCHEMBL1339005 | 0.79 | ALDH1A1 (0.42) | RXFP1EGFRKDM4EMAPTGABRA1 | |
| SCHEMBL1338090 | 0.77 | KDM4E (0.52) | HSD17B10KMT2ARXFP1MEN1KDM4E | |
| SCHEMBL24095575 | 0.77 | HSD17B10 (0.69) | HSD17B10DPP4KMT2ARXFP1MEN1 | |
| SCHEMBL3571739 | 0.77 | KDM4E (0.43) | HSD17B10DPP4KDM4EMAPTALDH1A1 | |
| SCHEMBL4765446 | 0.76 | KDM4E (0.42) | HSD17B10KMT2AMEN1KDM4EMAPT | |
| SCHEMBL1337044 | 0.76 | CXCR3 (0.39) | RXFP1MAPTGABRA1GABRG2GABRB3 | |
| SCHEMBL1337225 | 0.75 | HPGD (0.42) | HSD17B10KMT2AMEN1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524857-B2 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | SANOFI-AVENTIS (FR) | 2009-04-28 | — | — | US | claimed |
| US-7160895-B2 | Use of pyridoindolone derivatives for the preparation of medicinal products | SANOFI-AVENTIS (FR) | 2007-01-09 | — | — | US | claimed |
| EP-1385513-B1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | SANOFI AVENTIS (FR) | 2006-09-06 | — | — | EP | claimed |
| EP-1385512-B1 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | SANOFI AVENTIS (FR) | 2005-12-28 | — | — | EP | claimed |
| US-20050272760-A1 | Use of pyridoindolone derivatives for the preparation of medicinal products | SANOFI-AVENTIS (FR) | 2005-12-08 | — | — | US | claimed |
| US-6967203-B2 | Use of pyridoindolone derivatives for preparing anticancer medicines | SANOFI-AVENTIS (FR) | 2005-11-22 | — | — | US | claimed |
| US-20040122027-A1 | Use of pyridoindolone derivatives for preparing anticancer medicines | SANOFI (FR) | 2004-06-24 | — | — | US | claimed |
| US-20040122036-A1 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | SANOFI (FR) | 2004-06-24 | — | — | US | claimed |
| EP-1385513-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | Sanofi-Aventis (FR) | 2004-02-04 | — | — | EP | claimed |
| EP-1385512-A2 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | Sanofi-Aventis (FR) | 2004-02-04 | — | — | EP | claimed |
| WO-2002087574-A2 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | SANOFI-SYNTHELABO (FR) | 2002-11-07 | — | — | WO | claimed |
| WO-2002087575-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | SANOFI-SYNTHELABO (FR) | 2002-11-07 | — | — | WO | claimed |
| US-7524857-B2 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | SANOFI-AVENTIS (FR) | 2009-04-28 | — | — | US | disclosed |
| US-7160895-B2 | Use of pyridoindolone derivatives for the preparation of medicinal products | SANOFI-AVENTIS (FR) | 2007-01-09 | — | — | US | disclosed |
| EP-1385513-B1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | SANOFI AVENTIS (FR) | 2006-09-06 | — | — | EP | disclosed |
| EP-1385512-B1 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | SANOFI AVENTIS (FR) | 2005-12-28 | — | — | EP | disclosed |
| EP-1385512-A2 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | Sanofi-Aventis (FR) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385513-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | Sanofi-Aventis (FR) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002087574-A2 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | SANOFI-SYNTHELABO (FR) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002087575-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | SANOFI-SYNTHELABO (FR) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272760-A1 | Use of pyridoindolone derivatives for the preparation of medicinal products | DPYD, PNPO, ENTPD5 | HSD17B10 1238/4885DPP4 4201/4885KMT2A 4080/4885 |
| US-20040122036-A1 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | DPYD, DHFR, PNPO | HSD17B10 763/4885DPP4 1620/4885KMT2A 3931/4885 |
| US-20040122027-A1 | Use of pyridoindolone derivatives for preparing anticancer medicines | DPYD, PNPO, TYMP | HSD17B10 1176/4885DPP4 4302/4885KMT2A 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.